4//SEC Filing
Gayer Charles K 4
Accession 0001127602-22-027875
CIK 0000882796other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:48 PM ET
Size
5.2 KB
Accession
0001127602-22-027875
Insider Transaction Report
Form 4
Gayer Charles K
Vice President and CCO
Transactions
- Sale
Common Stock
2022-12-15$10.90/sh−6,100$66,490→ 211,610 total
Footnotes (2)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 20,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001800110
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 4:48 PM ET
- Size
- 5.2 KB